Vorasidenib pharmacokinetics in severe vs. normal liver function

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 interventional study compares the pharmacokinetics, safety, and tolerability of one 20 mg dose of vorasidenib between participants with severe hepatic impairment and matched controls with normal hepatic function. The study includes screening, a treatment period (Day 1–Day 4 in-house, Day 5–Day 43 with optional home stay), and follow-up, for up to 77 days total. Participants undergo blood tests, ECGs, vital signs, and physical exams to monitor safety and drug exposure. Inclusion requires cirrhosis with severe hepatic impairment (Child-Pugh 10–15) and clinical stability for at least 1 month, among other criteria. Lead sponsor is IRIS, with sites in Arizona, Florida, and Texas.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants with hepatic impairment:

* Diagnosis of cirrhosis due to parenchymal liver disease
* Considered to have a Child-Pugh score of 10 to 15, consistent with severe HI, and a documented medical history of liver disease. Participants must be clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to screening and are likely to remain stable throughout the study.
* Grade 0 or Grade 1 hepatic encephalopathy considered stable per Investigator assessment without exacerbation within the 6 months prior to screening.
* Currently on a stable medication regimen, defined as not starting new drug(s) or significantly changing drug dosage(s) within 14 days preceding Day 1.
* Non-hepatic abnormal laboratory values must be not clinically significant as judged by the Investigator (or designee) and the study medical monitor.
* Anemia secondary to hepatic disease is acceptable if hemoglobin is ≥ 9 g/dL and anemia symptoms are not clinically significant. Platelet count must be ≥ 35,000 platelets.
* QT interval corrected for heart rate using Fridericia's formula (QTcF) of ≤ 480 msec.

Matched-control participants:

* Healthy, with normal hepatic function with a Child-Pugh score below 5.
* Resting blood pressure of 90 to 140 mmHg (systolic) and 40 to 90 mmHg (diastolic).
* QTcF of ≤ 450 msec.
* Participant must match hepatically impaired participants with respect to sex, race, age (±10 years), smoking status (smoke or vape ≤ 10 cigarettes/day), and body mass index (±20%).

Exclusion Criteria for all participants:

* Women of childbearing potential (WOCBP) who are pregnant, lactating, or planning to become pregnant within 90 days after the dose of vorasidenib.
* The participant is using hormonal contraceptives
* Use of any other investigational drug or device within 30 days (or 5 half-lives if known, whichever is longer) before the dose of vorasidenib
* Consumption of any nutrients known to modulate CYP450 enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, Seville \[blood\] orange products) within 14 days before vorasidenib administration.
* Consumption of alcohol-containing foods or beverages or caffeine- or xanthine-containing foods or beverages (including, but not limited to, teas \[including decaffeinated teas\], coffees \[including decaffeinated coffees\], colas \[including decaffeinated colas\], energy drinks, gum containing caffeine, and chocolate (including foods and beverages containing chocolate) within 48 hours prior to admission
* Any history (within 5 years prior to screening) or presence of malignancy, except for adequately treated basal cell and squamous cell carcinoma of the skin
* History within the previous 12 months of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 12 oz beer, 5 oz wine, or 1.5 oz spirits)
* In the opinion of the Investigator, the participant is not suitable for entry into the study

Where it's running

• Arizona Clinical Trials
  Chandler, Arizona, United States Recruiting
• Orlando Clinical Research Center
  Orlando, Florida, United States Recruiting
• American Research Corporation
  San Antonio, Texas, United States Recruiting

Study contacts

• Study coordinator: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
• Email: scientificinformation@servier.com
• Phone: +33 1 55 72 60 00

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Vorasidenib for kids with Grade 2 glioma that has IDH mutations

  This study tests whether vorasidenib is safe and helps control disease in kids aged 12 to 18 with Grade 2 astrocytoma or oligodendroglioma carrying an IDH mutation.

  Recruiting at 5 sites Phase 2 Servier · Los Angeles, California and 4 other locations · NCT07286292

• S230815 for children with KCNT1-related developmental and epileptic encephalopathy

  This study will test whether the investigational medicine S230815 is safe, well tolerated, and affects seizures and related symptoms in children aged 2–12 who have KCNT1-related developmental and epileptic encephalopathy.

  Recruiting at 11 sites Phase 1/2 Servier · Orange, California and 14 other locations · NCT07227857

• Ivosidenib for adults with IDH1‑mutated cancers and liver or kidney impairment.

  This will test ivosidenib in adults with IDH1‑mutated cancers who have liver or kidney impairment to see how the drug is absorbed, processed, and tolerated.

  Recruiting at 17 sites Phase 1 Servier · Atlanta, Georgia and 19 other locations · NCT07006688

• Treatment for Myelodysplastic Syndromes with IDH1 Mutation

  This study is testing whether a new drug called ivosidenib can help people with myelodysplastic syndromes and an IDH1 mutation feel better compared to the standard treatment with azacitidine.

  Recruiting at 57 sites Phase 3 Servier · Denver, Colorado and 61 other locations · NCT06465953

• Ivosidenib for advanced or metastatic chondrosarcoma with IDH1 mutation

  This study is testing if a new pill called ivosidenib can help people with advanced chondrosarcoma that has an IDH1 mutation live longer and feel better compared to a placebo.

  Recruiting at 111 sites Phase 3 Servier · Los Angeles, California and 114 other locations · NCT06127407

• Treatment for adults with IDH1 mutation-positive acute myeloid leukemia who can't undergo intensive chemotherapy

  This study is testing if a combination of two medications can help adults with a specific type of leukemia who can't have strong chemotherapy.

  Recruiting at 10 sites Phase 3 Servier · Vienna and 14 other locations · NCT05907057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.